期刊
JOURNAL OF GENERAL VIROLOGY
卷 89, 期 -, 页码 2992-2997出版社
MICROBIOLOGY SOC
DOI: 10.1099/vir.0.2008/004440-0
关键词
-
资金
- EC DGR FP5
- EuroVacc Foundation
- NIHR Comprehensive Biomedical Research Centre at St Mary's Hospital, London
- University of California, Irvine, USA
- UK Medical Research Council
- UK Department of Health3
- Wellcome Trust Principal Research
- National Institute for Health Research [NF-SI-0507-10313] Funding Source: researchfish
The antibody responses elicited by immunization of humans with vaccinia virus (VACV) strains Lister, Dryvax and NYVAC have been determined and compared. Neutralizing antibodies against intracellular mature virus (IMV) and extracellular enveloped virus (EEV), and binding antibody titres (ELISA) against the EEV protein B5, the IMV proteins A27 and H3, and VACV-infected cell lysate were measured. Lister and Dryvax induced broadly similar antibody titres, consistent with the fact that these vaccines each protected against smallpox. In contrast, antibody titres induced by NYVAC were significantly lower than those induced by both Lister and Dryvax. Moreover, there were qualitative differences with NYVAC-immunized subjects failing to induce A27-specific antibodies. These observations suggest that although NYVAC is a safer VACV strain, it does not induce an optimal VACV-specific antibody response. However, NYVAC strains engineered to express antigens from other pathogens remain promising candidate vaccines for immunization against other diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据